We'll have to agree to disagree there - if you want to track the trajectory of the underlying business, especially when one-off non-cash expenses are being booked, EBIT is the only way to go.
"Competitor snapping at the heels"?? BEACON is a P2 study which only initiated this month so that compound is still 3-4 years away from approval, if it makes it at all.
Ann: Appendix 4E and Annual Report 2022, page-8
Add CUV (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$14.58 |
Change
-0.930(6.00%) |
Mkt cap ! $718.6M | |||
| Open | High | Low | Value | Volume |
| $15.35 | $15.74 | $14.23 | $4.173M | 285.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 500 | $14.56 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $14.58 | 1486 | 2 |
View Market Depth
| Last trade - 16.10pm 09/07/2024 (20 minute delay) ? |
| CUV (ASX) Chart |